Toggle Health Problems and D

The End of Alzheimer's and Dementia if adjust Vitamin D, B-12, Iron, Omega-3, etc.

End of Alzheimer's books. publications, videos, web - Dale Bredesen

ReCODE: The Reversal of Cognitive Decline = Mercola 2017

ReCODE: The Reversal of Cognitive Decline Mercola 2017
Story at-a-glance

  • Dr. Dale Bredesen’s ReCODE protocol evaluates 150 factors known to contribute to Alzheimer’s disease. This identifies your disease subtype or combination of subtypes, and an effective treatment protocol can be devised
  • Type 1 Alzheimer’s is primarily caused by inflammatory factors; type 2 involves atrophic responses; type 1.5 is a mix of inflammation and atrophy, and type 3 is primarily caused by toxic exposures
  • Only 5 percent of Alzheimer’s cases are “familial” Alzheimer’s disease, a genetic condition that causes early onset Alzheimer’s; the rest are caused by lifestyle factors over which we have a great deal of control; hence, we have the ability to improve or even reverse most cases of the disease

Includes interview and transcript of Dr. Bredesen, author

4 Alzheimer’s Subtypes

While these classifications have not become widely accepted yet, Bredesen has published two papers on Alzheimer’s subtypes, based on metabolic profiling.4 These include:

  • 1. Type 1, inflammatory (“hot”) Alzheimer’s: Patients present predominantly inflammatory symptoms. They have high-sensitivity C-reactive protein, interleukin 6 and tumor necrosis factor alpha, reflecting a chronic inflammatory state. When the NF-ĸB part of inflammation is activated, it also alters gene transcription. Two of the genes turned “on” are beta-secretase and gamma-secretase, the latter of which cleaves APP, thereby promoting synaptoclastic processes.
  • 2. Type 1.5, glycotoxic (sugar-toxic, “sweet, a mixed subtype: This is an in-between subtype that involves both inflammation and atrophy processes, due to insulin resistance and glucose-induced inflammation.
  • 3. Type 2, atrophic or “cold”Alzheimer’s: This is classified as patients presenting an atrophic response. While a completely different mechanism from inflammation, it produces the same end result — it pushes APP in the direction of creating amyloid plaques and Alzheimer’s cell signaling.
  • 4. Type 3, toxic (“vile”) Alzheimer’s: These are patients with toxic exposures. Many will have chronic inflammatory response syndrome (CIRS) markers, even though most do not fit the official criteria for CIRS. “They act like CIRS patients (in their labs, not necessarily symptoms) with dementia,” Bredesen explains.

Sections of the article include

  • If You’re ApoE4 Positive, Fasting Is Strongly Indicated to Avoid Alzheimer’s
  • Mitochondrial Dysfunction Is at the Heart of Alzheimer’s
  • The ReCODE protocol evaluates 150 different variables, including biochemistry, genetics and historical imaging, to determine which factors are most likely driving the disease.

Alzheimer’s Screening Tests

Test Recommended range
Ferritin ( Iron ) 40 to 60 ng/mL
GGT <16 U/L for men and < 9 U/L for women
25-hydroxy vitamin D 40 to 60 ng/mL
High-sensitivity CRP <0.9 mg/L
Fasting Insulin < 4.5 mg/dL
Omega-3 index and
Omega 6:3 ratio
Omega-3 index > 8 %
TNF alpha < 6.0
TSH Less than 2.0 microunits/mL
Free T3 3.2-4.2 pg/mL
Reverse T3 <20 ng/mL
Free T4 1.3-1.8 ng/mL
Serum copper and zinc ratio 0.8-1.2
Serum selenium 110-150 ng/mL
Glutathione 5.0-5.5 μm
Vitamin E (alpha tocopherol) 12-20 mcg/mL
Body mass index 18-25
ApoE4 (DNA test) See how many alleles you have: 0, 1 or 2
Vitamin B12 500-1,500
Hemoglobin A1c Less than 5.5
Homocysteine 4.4-10.8 mcmol/L

Annual summit on Alzheimer's prevention (June 2023, etc.)


Nov 2021 email from End of Alz organization - details and pricing

 Download the PDF from VitaminDWiki

Bredesen protocol and Parkinson's

26:31 The conditions that are associated with cognitive decline include the following:

  1. . Alzheimer’s disease, the most common form.
  2. . Lewy Body Disease.
  3. Parkinson’s.
  4. Vascular dementia.
  5. Normal pressure hydrocephalus. etc.
  6. Frontotemporal dementia,
  7. LATE. Limbic-predominant age-associated TDP-43 encephalopathy.
  8. Multiple Sclerosis.
  9. PSP. Progressive supranuclear palsy.
  10. Corticobasal degeneration.
  11. CTE, which is chronic traumatic encephalopathy.
  12. TBI. Traumatic brain injury.
  13. Post-COVID-19 related encephalopathy? Long haul?

VitaminDwiki - Overview Alzheimer's-Cognition and Vitamin D start with

See also VitaminDWiki

Cognitive category starts with the following

Very brief summary of Cognitive decline
Treatment : Vitamin D intervention slows or stops progression
Prevention : Many observational studies - perhaps Vitamin D prevents
Omega-3 both prevents and treats cognition
Wonder the benefits if both Vitamin D AND Omega-3 were to be used
Dementia page - 50 items

373 items in Cognition category

see also Overview Alzheimer's-Cognition and Vitamin D
Overview Parkinson's and Vitamin D

Studies in both categories of Cognition and:
Cardiovascular (7 studies), Genetics (9 studies), Vitamin D Receptor (16 studies), Omega-3 (49 studies), Intervention (19 studies), Meta-analyses (22 studies), Depression (23 studies), Parkinson's (22 studies)
Click here for details

Poor cognition 26 percent more likely if low Vitamin D (29 studies) – meta-analysis July 2017
Every schizophrenia measure was improved when vitamin D levels were normalized – June 2021
Cognitive Impairment and Dementia often associated with low Vitamin D – April 2020
IQ levels around the world are falling (perhaps lower Vitamin D, Iodine, or Omega-3)
Search VitaminDWiki for "WHITE MATTER" 325 items as of March 2023

Types of evidence that Vitamin D helps brain problems - 2014

See also web

There have been 2331 visits to this page

Attached files

ID Name Comment Uploaded Size Downloads
16604 End of Alz details and prices nov 2021_compressed.pdf admin 16 Nov, 2021 809.04 Kb 274
10958 Inhalational Alzheimer's disease.pdf admin 02 Dec, 2018 685.75 Kb 687
10957 Reversal of cognitive decline in Alzheimer's disease.pdf admin 02 Dec, 2018 528.97 Kb 693
8357 Alzheimer's B Vitamins.pdf admin 27 Aug, 2017 852.72 Kb 767